The Australian Government invests $40
million to provide patients affordable access to two new
medicine listings through the Pharmaceutical Benefit Scheme
(PBS)
LUND, Sweden, Aug. 26, 2019 /PRNewswire/ -- The Australian
Federal Health Minister Greg Hunt
announced on Sunday that Camurus' long-acting medication Buvidal®
Weekly and Monthly (buprenorphine) solutions for injection will be
listed on the PBS. From September, Buvidal® will be fully
subsidised as a part of a $40 million
investment by the Australian
Government.[1,2]
Over 110,000 Australians are currently struggling with opioid
dependence with increasing deaths from overdose.[3,4] Approximately
50,000 people receive treatments for their opioid dependence at
2,852 dosing points in Australia.
I his statement, the Health Minister notes that Buvidal®
provides a more flexible option for people to manage their
addiction, replacing daily treatment at pharmacy or dosing point
with weekly or monthly injections. This will remove costs for daily
dispensing and reduce travel times. For further information, see
https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/pbs-support-for-end-of-life-care-and-opioid-dependency.
Professor Nicholas Lintzeris,
Director of Drug and Alcohol Services, South East Sydney, a lead investigator in
clinical trials of Buvidal®, commented "The introduction of a once
weekly or once monthly treatment has potential to improve treatment
outcomes and reduce the daily burden and the stigma attached to the
daily supervised visits to a clinic or pharmacy faced by patients
on current daily medications."
For full Australian prescribing information of Buvidal® Weekly
and Buvidal® Monthly, see http://www.medicines.org.au.[5]
About Camurus
Camurus is a Swedish science-led biopharmaceutical company
committed to developing and commercialising innovative and
differentiated medicines for the treatment of severe and chronic
conditions. New drug products with best-in-class potential are
conceived based on the company's proprietary FluidCrystal® drug
delivery technologies and its extensive R&D expertise. Camurus'
clinical pipeline includes products for the treatment of cancer,
endocrine diseases, pain and addiction, which are developed
in-house and in collaboration with international pharmaceutical
companies. The company's shares are listed on Nasdaq Stockholm
under the ticker CAMX. For more information, visit
www.camurus.com.
References
- Media Release 25 August 2019,
The Hon. Greg Hunt MP, Minister of Health, Minister Assisting the
Prime Minister for the Public Service and Cabinet, Australia
https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/pbs-support-for-end-of-life-care-and-opioid-dependency
- Department of Health. PBAC Outcomes. March 2019
- Penington Institute. Australia's Annual Overdose Report
2018
- National Drug and Alcohol Research Centre. Trends in Drug
Induced Deaths in Australia
1997-2017
- Buvidal® Weekly and Monthly Australian Approved Product
Information
For more information
Fredrik Tiberg, President & CEO
Tel. +46(0)46-286-46-92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46(0)70-776-17-37
ir@camurus.com
This information was submitted for publication at 8:00 am CET on 26 August 2019.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/camurus-ab/r/australian-minister-for-health-announced-pbs-listing-of-buvidal--weekly-and-monthly-for-treatment-of,c2888324
The following files are available for download:
https://mb.cision.com/Main/13456/2888324/1095319.pdf
|
Press
release.pdf
|